Lv3
366 积分 2024-08-15 加入
An Innovative Approach to Optimize First‐In‐Human Minimal Anticipated Biological Effect Level Based Starting Dose in Oncology Trials for Bispecific T‐Cell Engagers: Experience from A Solid Tumor Bispecific T‐Cell Engager
19天前
已完结
T follicular helper cells and T peripheral helper cells in rheumatic and musculoskeletal diseases
1个月前
已完结
An Innovative Approach to Optimize First‐In‐Human Minimal Anticipated Biological Effect Level Based Starting Dose in Oncology Trials for Bispecific T‐Cell Engagers: Experience from A Solid Tumor Bispecific T‐Cell Engager
1个月前
已完结
Safety, pharmacokinetics and pharmacodynamics of SHR-1703, an innovative long-acting anti-interleukin-5 monoclonal antibody, in healthy subjects: a randomized, double-blind, dose-escalation, placebo-controlled phase I study
2个月前
已完结
MPBPK-TMDD models for mAbs: alternative models, comparison, and identifiability issues
2个月前
已完结
An Innovative Approach to Optimize First‐In‐Human Minimal Anticipated Biological Effect Level Based Starting Dose in Oncology Trials for Bispecific T‐Cell Engagers: Experience from A Solid Tumor Bispecific T‐Cell Engager
3个月前
已完结
Dose Finding in Drug Development edited by Naitee T
3个月前
已完结
Pharmacokinetics, Pharmacodynamics, and Tolerability of Single Ascending Doses of RCT-18 in Chinese Patients with Rheumatoid Arthritis
3个月前
已完结
Pathogenic cellular and molecular mediators in lupus nephritis
3个月前
已完结
Navigating First‐in‐Human and Early‐Phase Patient Studies: Study Designs, Risk Mitigation, and Population Selection Challenges
4个月前
已完结
皖公网安备34019202002308
